New hope for treating heart failure

Heart failure patients who are getting by on existing drug therapies can look forward to a far more effective medicine in the next five years or so, thanks to University of Alberta researchers.

Heart specialist Gavin Oudit and his research team discovered a molecule—angiotensin converting enzyme 2 (ACE2)—that works to restore balance to the pathways responsible for chronic and acute , including in patients with advanced heart failure who underwent heart transplants.

In conducting their research, Oudit and his team used genetic to discover to an extent not seen before how the renin-angiotensin system (RAS)—which regulates the body's sodium balance, fluid volume and blood pressure—is at play in both acute and .

It led to the creation of recombinant human ACE2, a new drug that was manufactured by Apeiron Biologics in collaboration with Oudit. It was bought by GlaxoSmithKline, which recently successfully completed phase II clinical trials that tested for the safety and efficacy of the drug on hundreds of patients. The new drug is expected to be on the market in the next three to five years.

Oudit added that using mapping technology has also made it possible to individualize the dose a patient needs, allowing for a truly personalized treatment plan for heart failure patients in the future. The study also broke ground by showing how ACE2 can be used in with heart failure.

About six million Canadians will develop heart failure, a common condition that most often happens after the heart has been damaged or weakened by heart attack or stroke. According to the Canadian Heart and Stroke Foundation, the two most common causes of heart failure are heart attacks and . When someone has heart failure, the heart either can't accept the inflow of blood or pump it out, or both.

"This research is a terrific example of how the university works together synergistically to develop world-class research and translate that into medicines that impact patient outcomes," added Oudit.


Explore further

Protective molecule, ACE2, also proving its worth in diabetic patients

More information: Ratnadeep Basu et al, Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure, Journal of the American College of Cardiology (2017). DOI: 10.1016/j.jacc.2016.11.064
Citation: New hope for treating heart failure (2017, March 8) retrieved 27 June 2019 from https://medicalxpress.com/news/2017-03-heart-failure.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
2 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more